Literature DB >> 29767259

Silencing of miR‑155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation.

Quan Luo1, Jingxin Zeng1, Wei Li1, Ling Lin1, Xin Zhou1, Xin Tian1, Weiyu Liu1, Lidan Zhang1, Xibao Zhang1.   

Abstract

Psoriasis is a dermatosis with the major clinical symptoms of scale, erythema and itching, and it has a long disease course. In addition, it is easily recurrent and refractory, greatly affecting the physical and mental health of patients. In the present study, it was hypothesized that the function of miR‑155 increases psoriasis‑induced inflammation and that its expression may be dependent on inflammasome activation. miR‑155 expression was examined by gene chip array and quantitative polymerase chain reaction analysis. miR‑155 expression levels were significantly increased in an in vivo model of psoriasis compared with normal tissues, as was the expression of NLR family pyrin domain containing 3 (NLRP3). In vitro, using keratinocyte‑induced HaCaT cells as a model for psoriasis, silencing of miR‑155 was confirmed to significantly decrease inflammation and NLRP3/caspase‑1 signaling. Activation of toll‑like receptor 4 (TLR4) enhanced the miR‑155‑induced inflammatory response in the in vitro keratinocyte model. Treatment with a TLR4 inhibitor or an NLRP3 inhibitor reversed the miR‑155‑mediated inflammation in the same cell system. The present study demonstrated that miR‑155 silencing suppressed psoriasis‑associated inflammatory responses through inflammasome NLRP3 regulation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29767259     DOI: 10.3892/ijmm.2018.3677

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH.

Authors:  Shashi Bala; Michal Ganz; Mrigya Babuta; Yuan Zhuang; Timea Csak; Charles D Calenda; Gyongyi Szabo
Journal:  Lab Invest       Date:  2021-08-27       Impact factor: 5.502

Review 2.  NOD-like receptors in autoimmune diseases.

Authors:  Li Chen; Shi-Qi Cao; Ze-Min Lin; Shi-Jun He; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2021-02-15       Impact factor: 6.150

Review 3.  Inflammasomes in Common Immune-Related Skin Diseases.

Authors:  Lili Tang; Fusheng Zhou
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

4.  Construction of a lncRNA-miRNA-mRNA network to determine the regulatory roles of lncRNAs in psoriasis.

Authors:  Qianqian Zhou; Qian Yu; Yu Gong; Zhicui Liu; Hui Xu; Yao Wang; Yuling Shi
Journal:  Exp Ther Med       Date:  2019-09-23       Impact factor: 2.447

Review 5.  The Role of Epigenetics in Autoimmune/Inflammatory Disease.

Authors:  Anna Elisa Andrea Surace; Christian M Hedrich
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

Review 6.  MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis.

Authors:  Sandra Domingo; Cristina Solé; Teresa Moliné; Berta Ferrer; Josefina Cortés-Hernández
Journal:  Cells       Date:  2020-12-10       Impact factor: 6.600

Review 7.  The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review.

Authors:  Magdalena Ciążyńska; Irmina Olejniczak-Staruch; Dorota Sobolewska-Sztychny; Joanna Narbutt; Małgorzata Skibińska; Aleksandra Lesiak
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 8.  TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.

Authors:  Jie Guo; Mengfan Liao; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-09-03       Impact factor: 5.712

9.  Acetylsalicylic Acid Suppresses Alcoholism-Induced Cognitive Impairment Associated with Atorvastatin Intake by Targeting Cerebral miRNA155 and NLRP3: In Vivo, and In Silico Study.

Authors:  Doaa I Mohamed; Dalia Alaa El-Din Aly El-Waseef; Enas S Nabih; Omnyah A El-Kharashi; Hanaa F Abd El-Kareem; Hebatallah H Abo Nahas; Basel A Abdel-Wahab; Yosra A Helmy; Samar Zuhair Alshawwa; Essa M Saied
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.